MX2022015623A - Terapia contra el cancer. - Google Patents

Terapia contra el cancer.

Info

Publication number
MX2022015623A
MX2022015623A MX2022015623A MX2022015623A MX2022015623A MX 2022015623 A MX2022015623 A MX 2022015623A MX 2022015623 A MX2022015623 A MX 2022015623A MX 2022015623 A MX2022015623 A MX 2022015623A MX 2022015623 A MX2022015623 A MX 2022015623A
Authority
MX
Mexico
Prior art keywords
therapy
cancer therapy
relates
live attenuated
present
Prior art date
Application number
MX2022015623A
Other languages
English (en)
Inventor
Hyam Levitsky
Livija Deban
Original Assignee
Prokarium Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prokarium Ltd filed Critical Prokarium Ltd
Publication of MX2022015623A publication Critical patent/MX2022015623A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)

Abstract

La presente invención se refiere al campo de la terapia contra el cáncer. En particular, la presente invención se refiere a una bacteria Gram-negativa atenuada viva para usarse en el tratamiento, reducción inhibición o control de una enfermedad neoplásica en un sujeto que se somete o que pretende someterse a inmunoterapia con una terapia de inhibidor de punto de control, terapia de células T adoptivas y/o una terapia T CAR alogénica o autóloga simultánea, separada o secuencialmente con la administración de la bacteria Gram-negativa atenuada viva.
MX2022015623A 2020-06-10 2021-06-10 Terapia contra el cancer. MX2022015623A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063037179P 2020-06-10 2020-06-10
EP20184698.7A EP3922255A1 (en) 2020-06-10 2020-07-08 Cancer therapy
PCT/EP2021/065698 WO2021250200A1 (en) 2020-06-10 2021-06-10 Cancer therapy

Publications (1)

Publication Number Publication Date
MX2022015623A true MX2022015623A (es) 2023-03-15

Family

ID=71607698

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015623A MX2022015623A (es) 2020-06-10 2021-06-10 Terapia contra el cancer.

Country Status (11)

Country Link
US (3) US11529378B2 (es)
EP (2) EP3922255A1 (es)
JP (1) JP2023529957A (es)
KR (1) KR20230023731A (es)
CN (1) CN116113426A (es)
AU (1) AU2021288622A1 (es)
BR (1) BR112022025245A2 (es)
CA (1) CA3186261A1 (es)
IL (1) IL298865A (es)
MX (1) MX2022015623A (es)
WO (1) WO2021250200A1 (es)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
GB9910812D0 (en) 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
GB0327056D0 (en) 2003-11-20 2003-12-24 Cobra Biolog Ltd Plasmid maintenance
US8221739B2 (en) * 2004-04-29 2012-07-17 Botanic Oil Innovations, Inc. Method of cancer treatment
GB201011046D0 (en) 2010-06-30 2010-08-18 Rph Pharmaceuticals Ab Plasmid maintenance
EP2801364A1 (en) * 2013-05-07 2014-11-12 Centre Hospitalier Universitaire Vaudois (CHUV) Salmonella strain for use in the treatment and/or prevention of cancer
AU2015289449A1 (en) * 2014-07-18 2017-02-09 Advaxis, Inc. Listeria-based immunogenic compositions for eliciting anti-tumor responses
BR112019009003A2 (pt) * 2016-11-04 2019-07-16 Vaximm Ag cepa atenuada de salmonela e composição farmacêutica
US11576936B2 (en) * 2016-12-07 2023-02-14 Salspera, Llc Methods of synergistic treatment of cancer
EP3495469A1 (en) 2017-12-07 2019-06-12 Prokarium Limited Vaccine compositions ii
WO2020047161A2 (en) * 2018-08-28 2020-03-05 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
JP2022506777A (ja) 2018-11-08 2022-01-17 シンロジック オペレーティング カンパニー インコーポレイテッド がんの処置において使用するための微生物および免疫モジュレーターの併用療法
US10806778B2 (en) 2019-01-30 2020-10-20 Prokarium Limited Modified strain of Salmonella enterica Typhi
JP2022522350A (ja) * 2019-02-27 2022-04-18 ザ ジェネラル ホスピタル コーポレイション 弱毒化サルモネラ・チフィムリウム（Ｓａｌｍｏｎｅｌｌａ ｔｙｐｈｉｍｕｒｉｕｍ）を使用する良性神経系腫瘍の処置
WO2021071468A1 (en) 2019-10-07 2021-04-15 Nantcell, Inc. Neoepitope vaccine and immune stimulant combinations and methods

Also Published As

Publication number Publication date
EP3922255A1 (en) 2021-12-15
US20230143897A1 (en) 2023-05-11
WO2021250200A1 (en) 2021-12-16
JP2023529957A (ja) 2023-07-12
AU2021288622A1 (en) 2023-02-02
US11529378B2 (en) 2022-12-20
KR20230023731A (ko) 2023-02-17
US20210386794A1 (en) 2021-12-16
CA3186261A1 (en) 2021-12-16
CN116113426A (zh) 2023-05-12
IL298865A (en) 2023-02-01
EP4164662A1 (en) 2023-04-19
BR112022025245A2 (pt) 2023-03-14
US20220354904A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
BR112021024966A2 (pt) Composições e métodos para administração subcutânea de imunoterapia de câncer
PH12020551908A1 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
MX2019000286A (es) Una combinación farmacéutica y método para la regulación del microentorno tumoral e inmunoterapia.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
Reginato et al. Photodynamic therapy downregulates the function of regulatory T cells in patients with esophageal squamous cell carcinoma
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
MX2020001727A (es) Terapia de combinacion.
MX2021013608A (es) Composiciones y métodos de fabricacion de celulas t.
ZA202300875B (en) Kat6 inhibitor methods and combinations for cancer treatment
PH12021550376A1 (en) Combination therapy
JOP20210245A1 (ar) طرق لعلاج الداء النشواني من النوع خفيف السلسلة
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
PH12015502266A1 (en) Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
MX2022015623A (es) Terapia contra el cancer.
BR112022019846A2 (pt) Método de tratamento de esclerose múltipla recorrente (rms), métodos para reduzir a taxa de recorrência anualizada (arr), reduzir o risco de experimentar ccdp12 e aumentar o tempo até o início de ccdp12 e compostos
BR112022010072A2 (pt) Métodos que empregam óxido nítrico gasoso para inibir crescimento de tumor
Abdollahi et al. The potential use of biogas producing microorganisms in radiation protection
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
MX2022006883A (es) Uso de isatuximab para el tratamiento del mieloma multiple recidivante y/o refractario.
MX2022000082A (es) Composiciones terapeuticas y metodos para tratar canceres.
MX2021013351A (es) Terapias de combinacion.
MX2023008835A (es) Métodos de tratamiento de la amiloidosis al.
MX2022003288A (es) Tratamiento con anticuerpos terapeuticos e interleucina-2 (il2).
MX2022015109A (es) Tratamiento de homocistinuria e hiperhomocisteinemia mediante el uso de cistationina-gamma-liasa.